clinical trial · NCT05687071
A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
Otsuka Pharmaceutical Co., Ltd.·phase3·completed·n = 130
Hyper-low-density Lipoprotein (LDL) Cholesterolemia180mg of ETC-1002(bempedoic acid)
brief summary
A Multicenter, Open-label Study to assess the safety and efficacy of ETC-1002 at 180 mg administered for 52 weeks in patients with hyper-LDL cholesterolemia
started
Feb 27, 2023
primary completion
Oct 5, 2024
completion
Nov 2, 2024
last updated
Feb 20, 2026
official title
A Multicenter, Open-label, Uncontrolled, Long-term Trial to Assess the Safety and Efficacy of ETC-1002 in Patients With Hyper-LDL Cholesterolemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol